Circulating concentrations of inflammatory biomarkers, including tumor necrosis factor-α and interleukins (e.g., IL-1, 10, 12, and 17); intestinal permeability markers (e.g., CD14 and intestinal fatty acid binding protein); and markers of endotoxemia (i.e., lipopolysaccharide and its binding protein) will be assessed by flow cytometry-based multiplex assays [27], enzyme-linked immunosorbent assay (ELISA) [28], and Limulus amebocyte lysate assay [29, 30], respectively. Here, FABP2 is linked to serum lipopolysaccharide activity.